Psychedelics in psychiatric disorders: Where are we now and where to next?
Tracks
Track 2
| Friday, November 1, 2024 |
| 2:10 PM - 2:55 PM |
Details
In this session panellists will deconstruct the recent FDA decision regarding the Lykos P3 clinical trial of MDMA in PTSD, the potential impact on global and Australian patients and markets in terms of drug development new treatment options and protocols, and the development of new therapeutics in the psychedelic space for patients with psychiatric disorders.
Speaker
Ms Sharon CHARLES
VP Clinical Operations
ProPharma
Panellist
Mr Roy Gustini
Commercial Growth Manager
Cortexa
Panellist
Professor Robyn Langham
Chief Medical Officer TGA (and HREC Chair
Royal Children’s Hospital, Melbourne
Panellist
